Lumakras: Uses, Dosage, Side Effects, Warnings - Drugs.com (2024)

Generic name: sotorasib
Dosage form: tablets
Drug class: Miscellaneous antineoplastics

Medically reviewed by Judith Stewart, BPharm. Last updated on Sep 21, 2023.

What is Lumakras?

Lumakras is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC):

  • that has spread to other parts of the body or cannot be removed by surgery, and
  • whose tumor has an abnormal KRAS G12C gene, and
  • who have received at least one prior treatment for their cancer.

Your healthcare provider will perform a test to make sure that Lumakras is right for you.

It is not known if this medicine is safe and effective in children.

Before taking Lumakras

Before you start treatment, tell your healthcare provider about all your medical conditions, including if you:

  • have liver problems
  • have lung or breathing problems other than lung cancer
  • are pregnant or plan to become pregnant. It is not known if Lumakras will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if Lumakras passes into your breast milk. Do not breastfeed during treatment, and for 1 week after the final dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, dietary and herbal supplements. Lumakras can affect the way some other medicines work, and some other medicines can affect the way Lumakras works.

Especially tell your healthcare provider if you take antacid medicines, including Proton Pump Inhibitor (PPI) medicines or H2 blockers during treatment. Ask your healthcare provider if you are not sure.

Lumakras pregnancy and breastfeeding warnings (more detail)

Related/similar drugs

Opdivo, methotrexate, Keytruda, Avastin, cisplatin, pembrolizumab, Tagrisso

How should I take Lumakras?

  • Take Lumakras exactly as your healthcare provider tells you to take it. Do not change your dose or stop taking Lumakras unless your healthcare provider tells you to.
  • Take Lumakras tablets 1 time each day, at about the same time each day.
  • Take the tablets with or without food.
  • Swallow the tablets whole. Do not chew, crush, or split tablets.
  • If you cannot swallow the tablets whole:
    • Place your daily dose in a glass of 4 ounces (120 mL) of non-carbonated, room temperature water without crushing the tablets. Do not use any other liquids.
    • Stir until the tablets are in small pieces (the tablets will not completely dissolve). The color of the mixture may be pale yellow to bright yellow.
    • Drink the tablet and water mixture right away or within 2 hours of preparing. Do not chew pieces of the tablet.
    • Rinse the glass with an additional 4 ounces (120 mL) of water and drink to make sure that you have taken the full dose.
  • If you do not drink the mixture right away, stir the mixture again before drinking.
  • If you take an antacid medicine, take Lumakras either 4 hours before or 10 hours after the antacid.
  • If you miss a dose of Lumakras, take the dose as soon as you remember. If it has been more than 6 hours, do not take the dose. Take your next dose at your regularly scheduled time the next day. Do not take 2 doses at the same time to make up for a missed dose.
  • If you vomit after taking a dose, do not take an extra dose. Take your next dose at your regularly scheduled time the next day.

Detailed Lumakras dosage information

Lumakrasside effects

Lumakras may cause serious side effects, including:

  • Liver problems. Lumakras may cause abnormal liver blood test results. Your healthcare provider should do blood tests before starting, and during treatment to check your liver function. Tell your healthcare provider right way if you get any signs or symptoms of liver problems, including:
    • your skin or the white part of your eyes turns yellow (jaundice)
    • dark or "tea-colored" urine
    • light-colored stools (bowel movements)
    • tiredness or weakness
    • nausea or vomiting
    • bleeding or bruising
    • loss of appetite
    • pain, aching, or tenderness on the right side of your stomach-area (abdomen)
  • Lung or breathing problems. Lumakras may cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough or fever.
    Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment if you develop side effects.

The most common side effects include:

  • diarrhea
  • muscle or bone pain
  • nausea
  • tiredness
  • liver problems
  • cough
  • changes in liver function tests
  • changes in certain other blood tests

These are not all the possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Amgen at 1-800-772-6436 (1-800-77-AMGEN).

What other drugs will affect Lumakras?

Sometimes it is not safe to use certain medications at the same time. Some drugs can affect your blood levels of other drugs you take, which may increase side effects or make the medications less effective.

Other drugs may interact with sotorasib, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

Lumakras drug interactions (more detail)

How should I store Lumakras?

  • Store Lumakras at room temperature between 68°F to 77°F (20°C to 25°C).
  • The bottle has a child-resistant closure.

Keep all medicines out of the reach of children and pets.

General information about the safe and effective use of Lumakras.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use this medicine for a condition for which it was not prescribed. Do not give it to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information that is written for healthcare professionals.

What are the ingredients in Lumakras?

Active Ingredient: sotorasib
Inactive Ingredients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium
stearate. Tablet film coating material contains polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and iron oxide yellow.

Popular FAQ

You will take Lumakras until your disease worsens or you have side effects that you cannot tolerate. Your doctor may be able to adjust your dose if you experience side effects like liver or lung toxicity, severe nausea or vomiting, severe diarrhea or other side effects. In some cases, you may need to stop treatment, as determined by your doctor.

Yes, Lumakras has an orphan drug designation from the FDA for KRAS G12C-positive NSCLC and colorectal cancer. It also holds a breakthrough therapy designation in the US and China.

Orphan drugs are medicines developed to help treat, prevent or diagnose rare “orphan” diseases, which are conditions that each affect fewer than 200,000 people in the United States. Companies that embark on developing orphan drugs get tax incentives, subsidies for clinical research, and the exclusive right to market the drugs for seven years.

In one clinical study with Lumakras, 45 out of 124 people (36%) saw their non-small cell lung cancer (NSCLC) tumors disappear or decrease in size by at least 30%.The median duration of response was 10 months. In another study, the 12-month progression-free survival rate was 24.8% with Lumakras vs. 10.1% with the chemotherapy agent docetaxel. Continue reading

More about Lumakras (sotorasib)

  • Check interactions
  • Compare alternatives
  • Reviews (1)
  • Drug images
  • Side effects
  • Dosage information
  • During pregnancy
  • FDA approval history
  • Drug class: miscellaneous antineoplastics
  • Breastfeeding
  • En español

Professional resources

  • Lumakras prescribing information
  • Sotorasib (AHFS Monograph)

Related treatment guides

  • Non Small Cell Lung Cancer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circ*mstances.

Medical Disclaimer

Lumakras: Uses, Dosage, Side Effects, Warnings - Drugs.com (2024)
Top Articles
Latest Posts
Article information

Author: Edmund Hettinger DC

Last Updated:

Views: 6711

Rating: 4.8 / 5 (78 voted)

Reviews: 85% of readers found this page helpful

Author information

Name: Edmund Hettinger DC

Birthday: 1994-08-17

Address: 2033 Gerhold Pine, Port Jocelyn, VA 12101-5654

Phone: +8524399971620

Job: Central Manufacturing Supervisor

Hobby: Jogging, Metalworking, Tai chi, Shopping, Puzzles, Rock climbing, Crocheting

Introduction: My name is Edmund Hettinger DC, I am a adventurous, colorful, gifted, determined, precious, open, colorful person who loves writing and wants to share my knowledge and understanding with you.